key: cord-0981207-66jrefp8
authors: Gupta, Tarana
title: COVID-19 and liver disease: Are we missing something?
date: 2022-02-27
journal: World J Hepatol
DOI: 10.4254/wjh.v14.i2.479
sha: 31e4020db3284c402f9700b6944d2fc563f31f72
doc_id: 981207
cord_uid: 66jrefp8

Since the coronavirus disease 2019 (COVID-19) has hit the world as a pandemic, researchers all over the world have worked on its diagnostics, prognosticating factors, etc. The present study showed liver enzymes, especially aspartate aminotransferase (AST) levels, to be high in non-survivors with raised AST/alanine aminotransferase ratio. Considering the non-specific nature of AST with its presence in organs other than liver such as muscle, heart, kidney and brain makes it difficult to interpret. Even pre-existing metabolic syndrome and non-alcoholic fatty liver disease are confounding factors for deranged liver functions detected during COVID-19 disease. Therefore, the results of the study should be taken with caution.

We read with great interest the article by "Madian et al [1] ". Limited data is available for hepatic injury in coronavirus disease 2019 (COVID-19) disease. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus causes direct cytopathic effect on hepatocytes. It enters the cell through angiotensin converting enzyme 2 (ACE2) receptors which are ubiquitously present on alveolar epithelium, liver, kidney and blood vessels etc. ACE2 receptors are present on endothelium of smaller blood vessels in liver, however, sparse on sinusoidal endothelium. Chai et al [2] reported higher ACE2 expression on cholangiocytes (59%) than hepatocytes (2.6%). They also suggested that liver dysfunction in COVID-19 is predominantly due to cholangiocyte dysfunction. The profound cytokine storm generated by lung injury also results in liver dysfunction. The drug-related hepatotoxicity related to the use of acetaminophen, remdesivir, lopinavir/ritonavir, azithromycin etc. during treatment of COVID-19 disease plays an additive role in causing deranged liver functions [3] . In addition, use of steroids especially in moderate to severe cases can also cause hepatitis B flare in occult hepatitis B patients.

Only a few studies could highlight liver function tests in patients with COVID-19 in non-cirrhotic patients. Limited studies have shown acute liver injury in 14%-53% of COVID-19 cases. In the present study, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were elevated in 31% and 3% among non-survivors respectively with 48% having AST/ALT ratio > 1.2. Zhang et al [4] showed raised AST levels more frequently in intensive care unit (ICU) patients (62%) than in non-ICU (25%) settings. Interestingly, the present study revealed an increased in-hospital mortality up to 11-and 13-fold with AST levels > 1 ULN and > 2 ULN respectively. Chen et al [5] analyzed biochemical profile of 113 deceased and 161 recovered patients in Wuhan, and found abnormal AST levels in 59 (52%) vs 25 (16%) and lower serum albumin in 74 (65%) vs 22 (14%) patients respectively. In the present study, authors also mentioned the possibility of raised AST levels due to muscle injury resulting from profound cytokine storm in COVID-19 illness, though they have documented normal creatine kinase (CK) values indicating liver involvement. AST is an enzyme which is found in liver, muscle, heart, kidney and brain. Therefore, raised AST levels should be taken with caution. The pattern of liver injury in COVID-19 disease is elevated AST levels more than ALT levels with higher gamma-glutamyltransferase (transpeptidase) (GGTP) values which is similar to alcoholic hepatitis.

We should not forget that non-alcoholic fatty liver disease (NAFLD) and obesity are associated with symptomatic, severe and complicated COVID-19 disease and is a potential confounder [6] . The studies assessing the role of liver injury on the course of COVID-19 illness have not screened patients for NAFLD, and we are not aware about their basic liver function tests before COVID-19. A pooled analysis of 8 studies in NAFLD and COVID-19 by Sachdeva et al[7] revealed NAFLD being a predictor of severe COVID-19 disease after adjustment of presence of obesity (OR: 2.3; 95%CI: 1.9-2.9, P < 0.001). Therefore, it may be too early to depend alone on AST levels for the severity and outcome of COVID-19 illness.

Hepatocellular injury and the mortality risk among patients with COVID-19: A retrospective cohort study

Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Liver injury in COVID-19: management and challenges

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression -The debate continues

NAFLD and COVID-19: a Pooled Analysis